A phase I study of CEP-701 [lestaurtinib] in patients with refractory neuroblastoma (IND 67 722).
Latest Information Update: 12 Apr 2023
At a glance
- Drugs Lestaurtinib (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacokinetics
- 30 Apr 2013 Planned end date changed from 1 Sep 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 26 Apr 2012 Additional trial location (Canada) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 Planned end date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.